Aerie Pharmaceuticals, a clinical-stage biotech developing treatments for glaucoma and other eye diseases, announced terms for its IPO on Tuesday. The Bedminster, NJ-based company plans to raise $68 million by offering 5.3 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Aerie Pharmaceuticals would command a market value of $264 million.
Aerie Pharmaceuticals, which was founded in 2005, plans to list on the NASDAQ under the symbol AERI. Aerie Pharmaceuticals initially filed confidentially on May 13, 2013. RBC Capital Markets and Stifel are the joint bookrunners on the deal.
